Summary
Chris Masterjohn explores the relationship between glutathione, vitamin C, and cancer treatment through IV drips. He examines the biochemical mechanisms by which high-dose vitamin C and glutathione interact, their potential roles in cancer therapy, and the evidence supporting or challenging their therapeutic use.
Key Points
- High-dose vitamin C IV drips generate hydrogen peroxide that may target cancer cells
- Glutathione plays a critical role in the antioxidant defense system
- The interaction between glutathione and vitamin C affects their therapeutic potential
- IV delivery bypasses absorption limitations of oral supplementation
- Evidence for anti-cancer effects remains mixed but mechanistically plausible
Key Moments
IV vitamin C kills cancer but raises oxalate risk
High-dose IV vitamin C acts as a pro-oxidant to kill cancer cells, but oral doses above 400mg can raise oxalate levels in some people.
"Oral doses of 2,000mg of vitamin C per day raise oxalate levels in most people, and as little as 400mg raises oxalate in some people."
